HEALTHNEW SCIENTIST
First-of-kind Guillain-Barré drug switches off part of immune system
A treatment that inhibits the immune system component responsible for Guillain-Barré syndrome could become the first targeted therapy approved for the autoimmune condition.
Related Signal
Adjacent reporting
- A revolutionary cancer treatment could transform autoimmune disease
- Drug slashes risk of developing rheumatoid arthritis by 60 percent, study suggests
- Lupus patients in England in remission after pioneering NHS trial of GM therapy
- Best treatment for multiple sclerosis may be antivirals
- New depression treatment targets the immune system instead of the brain